deltatrials
Not Yet Recruiting OBSERVATIONAL NCT07529756

The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry (CALIBER)

The ReCAna for Lower ExtremIty Venous OBstructions and In-StEnt Restenosis Registry ("The CALIBER Registry")

Sponsor: Intervene, Inc.

Conditions Chronic Venous Disease Chronic Venous Insufficiency, CVI Embolism and Thrombosis Thrombectomy Thrombosis (Stent Thrombosis) Thrombosis, Venous Venous Thrombosis
Interventions mechanical thrombectomy
Updated 1 time since 2026 Last updated: Apr 13, 2026 Started: Jun 1, 2026 Primary completion: Dec 1, 2028 Completion: Mar 1, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT07529756, this observational or N/A phase trial focuses on Chronic Venous Disease and Chronic Venous Insufficiency, CVI and remains actively recruiting participants. Sponsored by Intervene, Inc., it has been updated 1 time since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Study Description(click to expand)

The CALIBER Registry is a prospective, multi-center, non-randomized, non-interventional (observational) registry of the Recana Thrombectomy Catheter System for the treatment of symptomatic venous obstruction and occlusions. Commensurate with the continuum of care and usual practice for the follow-up of the study population, subjects are assessed at post-procedure/discharge, 30-day (30D), 180-day (180D) and 365-day (365D) post-index procedure \[reporting on these timepoints are based on standard of care clinic visits that occur closest to timepoints at 30D, 180D and 365D post-procedure\].

The CALIBER Registry is a prospective, multi-center, non-randomized, non-interventional (observational) registry of the Recana Thrombectomy Catheter System for the treatment of symptomatic venous obstruction and occlusions. Commensurate with the continuum of care and usual practice for the follow-up of the study population, subjects are assessed at post-procedure/discharge, 30-day (30D), 180-day (180D) and 365-day (365D) post-index procedure \[reporting on these timepoints are based on standard of care clinic visits that occur closest to timepoints at 30D, 180D and 365D post-procedure\].

Status Flow

Apr 16, 2026 – present · 3 months · daily APINot Yet Recruiting

Change History

1 version recorded
Not Yet Recruiting [daily]

Eligibility Summary

The goal of this observational study is to gather additional safety and performance (effectiveness) data on the device for the treatment of symptomatic lower extremity venous obstructions and occlusions. The main questions the study aims to answer are: * What is the observed rate of safety events through the 30-day follow-up? * What is the rate of technical success (acute procedural success) achieved at the index procedure? Participants already undergoing treatment with the Recana as part of their regular medical care will be followed for 1 year.

Contact Information

Sponsor contact:
  • Intervene, Inc.
Data source: ClinicalTrials.gov

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.